Spero Therapeutics, Inc. (SPRO) P/E Ratio History
Historical price-to-earnings valuation from 2023 to 2024
Loading P/E history...
SPRO Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Spero Therapeutics, Inc. (SPRO) trades at a price-to-earnings ratio of -2.0x, with a stock price of $2.51 and trailing twelve-month earnings per share of $-0.78.
The current P/E is 114% below its 5-year average of 14.4x. Over the past five years, SPRO's P/E has ranged from a low of 3.3x to a high of 41.4x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, SPRO trades at a 109% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, SPRO trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our SPRO DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
SPRO P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $4B | 9.9Lowest | - | +68%Best | |
| $151B | 19.5 | - | -4% | |
| $277B | 15.4 | 0.73Best | +8% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
SPRO Historical P/E Data (2023–2024)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $1.34 | $0.07 | 19.1x | +33% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $1.30 | $0.33 | 3.9x | -73% |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $1.72 | $0.43 | 4.0x | -72% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $1.47 | $0.44 | 3.3x | -77% |
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $1.21 | $0.03 | 41.4x | +188% |
Average P/E for displayed period: 14.4x
See SPRO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SPRO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SPRO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSPRO — Frequently Asked Questions
Quick answers to the most common questions about buying SPRO stock.
Is SPRO stock overvalued or undervalued?
SPRO trades at -2.0x P/E, below its 5-year average of 14.4x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does SPRO's valuation compare to peers?
Spero Therapeutics, Inc. P/E of -2.0x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is SPRO's PEG ratio?
SPRO PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2023-2024.